21:44 , Apr 2, 2019 |  BC Innovations  |  Distillery Techniques

Dual-targeting liposomes for cancer therapy delivery

TECHNIQUES CATEGORY: Drug delivery TECHNOLOGY: Nanoparticles Dual-targeting liposomes could be used to deliver cancer therapies. Generation of the liposomes involves two steps: screening human cancer cell lines against a 68-gene panel of common cancer targets...
22:56 , Sep 5, 2018 |  BC Extra  |  Preclinical News

Two papers open door to T cell brain entry for glioblastoma therapy

Publisher’s note: On Feb. 20, the authors of the Nature paper cited below retracted it due to issues with figure presentation and underlying data. Two new studies have proposed solutions to different barriers that prevent...
15:21 , Jul 19, 2018 |  BC Innovations  |  Translation in Brief

Inflammatory images

A University of Calgary team has implicated the inflammasome in acute kidney injury induced by contrast imaging agents and identified targets that could help prevent it. In patients with diminished renal function, such as those...
15:31 , May 25, 2018 |  BC Week In Review  |  Clinical News

Bavarian Nordic's ProstVac misses OS endpoint in Phase III for CRPC

Bavarian Nordic A/S (CSE:BAVA) said ProstVac rilimogene galvacirepvec alone and in combination with GM-CSF both missed the primary endpoint of improving overall survival (OS) vs. placebo in the Phase III PROSPECT trial to treat metastatic...
15:23 , Feb 23, 2018 |  BC Week In Review  |  Company News

Merck buying oncolytic virus play Viralytics for $398M

Merck & Co. Inc. (NYSE:MRK) will acquire oncolytic immunotherapy company Viralytics Ltd. (ASX:VLA; OTCQX:VRACY) for A$1.75 per share, or A$502 million ($398 million). The price is a 182% premium to Viralytics’ close of A$0.62 on...
22:22 , Feb 21, 2018 |  BC Extra  |  Company News

Merck buying oncolytic virus play Viralytics for $398M

Merck & Co. Inc. (NYSE:MRK) will acquire oncolytic immunotherapy company Viralytics Ltd. (ASX:VLA; OTCQX:VRACY) for A$1.75 per share, or A$502 million ($398 million). The price is a 182% premium to Viralytics’ close of A$0.62 on...
00:51 , Jan 31, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Targeting domains Antibodies targeting CDCP1 and other extracellular antigens up-regulated by Ras could be used to deliver cytotoxic drug payloads to Ras-mutant cancers. Comparative mass spectrometry-based analysis of human epithelial cell lines expressing the...
23:13 , Sep 15, 2017 |  BC Extra  |  Financial News

Bavarian Nordic plummets on Phase III CRPC failure of ProstVac

Bavarian Nordic A/S (CSE:BAVA) sank DKK213.50 (48%) to DKK230, losing DKK6.8 billion ($1.1 billion) in market cap, on Friday after an IDMC recommended discontinuing for futility the Phase III PROSPECT trial of ProstVac rilimogene galvacirepvec...
21:09 , Sep 15, 2017 |  BC Week In Review  |  Clinical News

IDMC recommends discontinuation of Phase III CRPC of ProstVac

Bavarian Nordic A/S (CSE:BAVA) said an IDMC recommended discontinuing for futility the Phase III PROSPECT trial of ProstVac rilimogene galvacirepvec to treat metastatic castration-resistant prostate cancer (CRPC) based on a preplanned interim analysis. The primary...
23:17 , Sep 14, 2017 |  BC Extra  |  Clinical News

IDMC recommends discontinuation of Phase III CRPC trial of ProstVac

Bavarian Nordic A/S (CSE:BAVA) said an IDMC recommended discontinuing for futility the Phase III PROSPECT trial of ProstVac rilimogene galvacirepvec to treat metastatic castration-resistant prostate cancer based on a preplanned interim analysis. The primary endpoint...